ALS, Lou Gehrig’s Disease Clinical Trial 20203079

[LCID Study Number: 20203079]

Phase 3b, Multicenter, Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Oral Edaravone Administered for a Period of 48 Weeks in Subjects With Amyotrophic Lateral Sclerosis (ALS)

The purpose of this study is to evaluate and compare the efficacy of two dosing regimens of oral edaravone in subjects with amyotrophic lateral sclerosis (ALS).

Disease/Condition: ALS, Lou Gehrig’s Disease

Department: Gastroenterology

Location(s): Lahey Hospital & Medical Center (Burlington)

Primary Contact Email: tanya.l.fennell@lahey.org

Primary Contact Phone: 781-744-2400